Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
Rhea-AI Summary
Certara (Nasdaq: CERT) announced it will release its second quarter 2026 financial results before the market opens on Tuesday, August 4, 2026. Company management will hold a conference call at 8:30 AM ET, with live and archived webcast access via the Investors section of Certara’s website.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings report date: CERT +3.12% in the Jul 16 session
In the Jul 16 session, CERT gained 3.12%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.4% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Earnings date notice | Positive | +2.6% | Set timing for Q1 2026 results and accompanying investor call. |
| Jan 29 | Earnings date notice | Negative | -1.5% | Announced Q4 and full-year 2025 results release schedule and call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings date announcements have produced a mildly positive average move of 0.55% for CERT, but individual reactions have been mixed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.
Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance.
A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.
About Certara
Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.
Investor Relations Contact:
Erik Abdow
Gilmartin Group
ir@certara.com
Media Contact:
Alyssa Horowitz
certara@pancomm.com
